Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FXR: a target for cholestatic syndromes?

Shi-Ying Cai1, James L Boyer

  • 1Liver Center, Department of Medicine, Yale University School of Medicine, P.O. Box 208019, New Haven, CT 06520-8019, USA.

Expert Opinion on Therapeutic Targets
|May 19, 2006
PubMed
Summary

The nuclear farnesoid X receptor (FXR) regulates bile acid balance. FXR ligand therapy is explored for cholestatic liver diseases, addressing gene regulation and potential concerns.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Utility of Elastography in Discriminating Stages of Liver Fibrosis and Risk Stratification in Patients With Primary Sclerosing Cholangitis: A Systematic Review.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study.

Alimentary pharmacology & therapeutics·2026
Same author

Conjugated bile acid-driven CD14<sup>+</sup>CD16<sup>+</sup> monocyte infiltration promotes cholestatic liver injury by enhancing hepatocyte necroptosis.

JHEP reports : innovation in hepatology·2025
Same author

Liver Lymphatic Dysfunction as a Driver of Fibrosis and Cirrhosis Progression.

bioRxiv : the preprint server for biology·2025
Same author

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Hepatology communications·2024
Same author

Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population.

Science translational medicine·2024

Area of Science:

  • Hepatology and Molecular Biology
  • Endocrinology
  • Gastroenterology

Background:

  • The nuclear farnesoid X receptor (FXR) is crucial for bile acid homeostasis in humans.
  • FXR regulates key genes in bile acid synthesis, metabolism, and transport (e.g., CYP7A1, BSEP, MDR3).
  • Dysregulation of these genes is implicated in cholestatic liver diseases.

Purpose of the Study:

  • To review the therapeutic rationale for using FXR ligand therapy in cholestatic liver disorders.
  • To discuss the potential benefits and concerns associated with FXR-targeted treatments.

Main Methods:

  • Literature review of studies on FXR function in bile acid homeostasis.
  • Analysis of gene expression patterns in cholestatic liver diseases.
  • Examination of clinical data and preclinical findings related to FXR agonists.

Main Results:

  • FXR activation influences multiple genes critical for bile acid transport and metabolism.
  • Targeting FXR offers a potential strategy for managing cholestatic conditions.
  • Understanding FXR's role is key to developing effective therapies.

Conclusions:

  • FXR ligand therapy presents a promising avenue for treating cholestatic liver diseases.
  • Further research is needed to fully elucidate the risks and benefits.
  • Personalized approaches may be required for optimal FXR-based treatment.

Related Experiment Videos